SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
Abstract Objective To investigate the serologic response, predictors of response, and clinical outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis (RMS) from DAYBREAK. Metho...
Main Authors: | Bruce A. C. Cree, Rachel Maddux, Amit Bar‐Or, Hans‐Peter Hartung, Amandeep Kaur, Elizabeth Brown, Yicong Li, Yanhua Hu, James K. Sheffield, Diego Silva, Sarah Harris |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-10-01
|
Series: | Annals of Clinical and Translational Neurology |
Online Access: | https://doi.org/10.1002/acn3.51862 |
Similar Items
-
067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials
by: Jeffrey A Cohen, et al.
Published: (2021-08-01) -
An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
by: Fronza M, et al.
Published: (2021-05-01) -
Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
by: Grace Lassiter, et al.
Published: (2020-12-01) -
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
by: Daniel Kantor, et al.
Published: (2023-03-01) -
Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Yue Sun, et al.
Published: (2020-11-01)